Mebanazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mebanazine
Accession Number
DB09248
Type
Small Molecule
Groups
Withdrawn
Description

Mebanazine (trade name Actomol) is a monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was previously used as an antidepressant in the 1960s, but has since been discontinued.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Actomol
Categories
UNII
Z5R55CJ4CG
CAS number
65-64-5
Weight
Average: 136.198
Monoisotopic: 136.100048394
Chemical Formula
C8H12N2
InChI Key
HHRZAEJMHSGZNP-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2/c1-7(10-9)8-5-3-2-4-6-8/h2-7,10H,9H2,1H3
IUPAC Name
(1-phenylethyl)hydrazine
SMILES
CC(NN)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with (S)-Warfarin.
2,4-thiazolidinedioneMebanazine may increase the hypoglycemic activities of 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylamphetamineMebanazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineMebanazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineMebanazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineMebanazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineMebanazine may increase the hypertensive activities of 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Mebanazine.
Food Interactions
Not Available

References

General References
  1. Gilmour SJ: Clinical trial of mebanazine--a new monoamine oxidase inhibitor. Br J Psychiatry. 1965 Sep;111(478):899-902. [PubMed:5889715]
  2. Barker JC, Jan IA, Enoch MD: A controlled trial of mebanazine ('Actomol') in depression. Br J Psychiatry. 1965 Nov;111(480):1095-100. [PubMed:5320546]
  3. Knott F: A preliminary trial of mebanazine in depressive states. J New Drugs. 1965 Nov-Dec;5(6):345-7. [PubMed:5327282]
External Links
PubChem Compound
6179
PubChem Substance
310265151
ChemSpider
5944
ChEBI
134728
ChEMBL
CHEMBL1909283
Wikipedia
Mebanazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.6 mg/mLALOGPS
logP1.24ALOGPS
logP1.33ChemAxon
logS-1.1ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity53.93 m3·mol-1ChemAxon
Polarizability15.65 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Alkylhydrazines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Alkylhydrazine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Hydrazine derivative / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 21:57 / Updated on November 02, 2018 07:00